Abstract: Embodiments of the disclosure include treatments of subconcussive and/or concussive brain damage by administering fibroblasts and/or fibroblasts cultured with one or more types of immunocytes. In one specific embodiment fibroblasts are cultured with monocytes in the presence of patient-specific T cells, and subsequently the T cells are re-administered into the patient. In one particular embodiment, products derived from fibroblast-immunocyte mixtures are comprised of cellular lysate, apoptotic bodies, exosomes, and/or other microvesicles. In one embodiment, the fibroblast cells and/or products derived from the fibroblast cells are administered subsequent to one or multiple head injuries. In other embodiments, products are administered in combination with neurorestorative and/or neuroprotective interventions.

Abstract: The present invention describes mRNA usage improving and/or translation-enhancing nucleic acid sequences, nucleic acid constructs comprising such sequences, and host cells comprising such nucleic acid constructs. The invention further pertains to a method for expressing a protein of interest in a cell or organism using such nucleic acid sequences, as well as their uses for increasing integration of such nucleic acid construct into a genome, for enhancing mRNA usage and/or translation of a recombinantly expressed polypeptide, and for increasing the number of transformants upon transformation of a cell with such nucleic acid construct.

Abstract: A method for manufacturing an extracellular matrix composition includes providing a gel, carrying out a crosslinking treatment, carrying out a single type cell culture, carrying out a decrosslinking treatment, and carrying out an extraction treatment. The crosslinking treatment includes adding a crosslinking agent to the gel to obtain a crosslinked gel. The cell culture includes implanting cells of a singular type on the crosslinked gel and incubating the cells by adding a culture solution. The decrosslinking treatment includes adding a decrosslinking agent to the crosslinked gel to obtain a decrosslinked mixture that contains an extracellular matrix. The extraction treatment includes filtering the decrosslinked mixture to obtain the extracellular matrix composition that is in a liquid state.

Abstract: Provided herein are systems, methods, and cryoprotective solutions for reversible cryopreservation of biological specimens, whole organs, and whole organisms. Exemplary methods include loading a cryoprotective agent into the biological specimen, cooling the biological specimen to a cryogenic temperature for preservation, storing the biological specimen at a preservation temperature state to preserve the biological specimen, rewarming the biological specimen by increasing a temperature of the biological specimen above the preservation temperature state, and unloading the cryoprotective agent from the biological specimen. The cooling is performed at a first rate to reduce ice formation, substantially homogeneously to reduce propensity for cracking of the preserved biological specimen, and at a first pressure to prevent or reduce ice expansion within the preserved biological specimen.

Abstract: The present disclosure provides a newly-identified transitional cell state in alveolar regeneration, models to ablate lung alveolar type-1 cells that leads to lung fibrosis and emphysema, a scalable, an ex vivo lung fibrosis model that uses co-cultured lung fibroblasts and pre-alveolar type-1 transitional cell state (PATS) for the use of disease modeling and drug screening, and methods of using same.

Abstract: Modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. Embodiments of the invention further relate to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening, methods for the preparation of a modified NK-92 that is specific for a target antigen of a target cell in a subject, and to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

Abstract: The disclosure is directed to a method for seed train expansion of adherent cells comprising culturing cells with a serum-supplemented growth medium in a N-2 vessel; removing the cells from the serum-supplemented medium; inoculating the cells from step into a serum-free growth medium in a N-1 vessel; culturing the cells in the N-1 vessel under suspension conditions; and inoculating a growth medium in a bioreactor with the suspension-cultured cells. In some aspects, the adherent cells are not suspension-adapted. In some aspects, the adherent cells are suspension-adapted. In some aspects, the adherent cells produced by the seed train expansion method are used to produce viral vectors. In some aspects, the viral vectors are AAV vectors.

Abstract: The instant disclosure is directed to a method for vascularizing a pancreatic islet comprising culturing the pancreatic islet or ?-cells with an endothelial cell comprising an exogenous nucleic acid encoding an ETV2 transcription factor under conditions wherein the endothelial cell expresses the ETV2 transcription factor. The instant disclosure is further directed to a method for making a vascularized ?-cell organoid comprising culturing the pancreatic islet or ?-cells with an endothelial cell comprising an exogenous nucleic acid encoding an ETV2 transcription factor under conditions wherein the endothelial cell expresses the ETV2 transcription factor. Disclosed also are vascularized islets and vascularized ?-cell organoids produced by the methods of the instant disclosure, as well as methods for using the same.

Abstract: The present invention relates to a low-serum medium composition for culturing Vero cells, and a method for culturing Vero cells and a method for producing a virus, both using the same.

Abstract: A culture container for culturing epithelial cells, includes an upper container, a lid member configured to airtightly fit with an opening portion of the upper container, and a lower container configured to accommodate the upper container and a cell culture medium, in which at least a part of an area of the upper container in contact with the cell culture medium is formed of a membrane that is permeable to at least a part of components of the cell culture medium and impermeable to a cell, and a material of the lid member has an oxygen permeability coefficient of 1.0×10?6 cm3 cm/(cm2·sec·atm) or less.

Abstract: An object of the invention is to provide a novel pharmaceutical composition. The pharmaceutical composition of the disclosure contains a DNA encoding a suicide gene having at least one intron sequence. The intron sequence has a donor sequence or an acceptor sequence to be used in a tumor cell with abnormal splicing not in a normal cell. In a transcript of the DNA, the suicide gene is expressed when the intron is abnormally spliced and the suicide gene is not expressed when the intron is not abnormally spliced.

Abstract: In various aspects and embodiments the invention provides a method of treating multiple sclerosis in a subject in need thereof, the method comprising administering to the subject an effective amount of an oligodendrocyte-derived extracellular vesicle.

Abstract: Adult form glycogen storage disease type III (GSD III) is an orphan neuromuscular disorder caused by a deficiency of glycogen debranching enzyme. Long-term complications include progressive liver fibrosis, hepatic failure, and end-stage liver cirrhosis, and progressive muscle myopathy. Presently, there are no clinically approved therapies or cures for GSD III. Disclosed herein are compositions for and methods of treating and/or preventing GSD III disease progression.

Abstract: Described herein are compositions and methods for therapeutic delivery using an engineered viral vector. The engineered viral vector provided herein can improve therapeutic delivery, increase targeting efficiency, and decrease off-targeting or adverse effects.

Abstract: The present disclosure provides methods of producing hepatocytes from induced pluripotent stem cells. Further provided herein are methods of using the hepatocytes for the treatment of a liver disease.

Abstract: The present invention relates to stem cells derived from a multi-layered cellular structure or blastocyst structure, compositions comprising the same, and methods for obtaining the same.

Abstract: This document relates to methods and materials for making and using cardiopoetic stem cells. For example, methods and materials for delivering one or more nucleic acids (e.g., one or more RNAs) encoding one or more early mesodermal transcription factors to a stem cell to generate a cardiopoetic stem cell are provided.

Abstract: Provided are novel recombinant proteins that are capable of self-crystallization and exhibit desirable physical properties such as enhanced cellular uptake or and endoso-mal escape. Polynucleotides encoding the recombinant proteins as well as methods of making and using such proteins are also described.

Abstract: Herein is described a method devised to cryopreserve mosquito eggs, viable upon subsequent thawing. The method reproducibly yields >25% hatched first instar larvae of Anopheles-species mosquitoes from cryopreserved eggs. The majority of hatched larvae continue to develop normally (87% pupation), through to adults (98%, 50% of which are female) which subsequently blood feed and produce viable second generation embryos that also develop normally. Adult mosquitoes obtained from cryopreserved embryos are able to be infected with Plasmodium falciparum gametocytes and produce salivary gland sporozoites in similar numbers to control mosquitoes.

Abstract: The present application provides a helper plasmid for preparing a recombinant adeno-associated virus (rAAV), including: 1) a coding sequence of an AAV Rep protein and a coding sequence of an AAV Cap protein; 2) at least one promoter sequence; and 3) at least one DA?sequence or AD? sequence, wherein the AD? sequence is a reverse complementary sequence of the DA? sequence. The present application also provides a method for increasing a production capacity of a rAAV using the helper plasmid. With an AD? sequence or a DA? sequence, the helper plasmid provided in the present application can significantly increase an AAV yield of a cell.